Altimmune Outlook: Where Pemvidutide Phase 3 Is Heading In 2026

Altimmune, Inc. closed a $75 million direct offering to fund Phase 3 pemvidutide trials for MASH. Learn more about ALT stock ...

Big Pharma's Earnings Week: Strong Performance, Obesity Wars, LOE Management And More

Big Pharma delivered strong Q4 2025 results, with most companies beating revenue and EPS expectations and providing generally solid 2026 guidance. Eli Lilly solidified its leadership in obesity and ...
Undark Magazine

How a Croatian Lab Spawned a Buzzy Peptide Now Popular With MAHA

The gray market is awash with BPC-157, a drug hyped as a cure-all, but unapproved by the FDA. Will RFK Jr. change that?
STAT

From Croatia to MAHA: How an unapproved drug became the next hot peptide

BPC-157 hasn't been approved by the FDA. But that hasn't stopped this buzzy drug from gaining traction – and attention from MAHA.
Harvard Business Review

Hacking Tech’s Diversity Problem

When Google, Yahoo, LinkedIn, and Facebook disclosed their woefully low levels of female employment in the summer of 2014, admitting that they had a lot of work to do to improve them, they signaled a ...
Nature

Breaking into the black box of artificial intelligence

In February 2020, with COVID-19 spreading rapidly around the globe and antigen tests hard to come by, some physicians turned to artificial intelligence (AI) to try to diagnose cases 1. Some ...